We are experts in enabling ultra-sensitive immunoassays for research and clinical use with over 35 years of experience on the front line of infectious disease pandemics. Detection and monitoring of Low Abundance Proteins (LAPs) is a vital tool in the war against disease and viral pandemics past, present, and future. Our recently patented BOLD technology platform and Exazym® reagent kits deliver a life science tools breakthrough that enables ultra-sensitive signal amplification for any ELISA immunoassay. This technology has the potential to revolutionise the field of immunoassay, allowing for more accurate and reliable results. BOLD is a cost-effective solution that can be used in a variety of settings, from research laboratories to clinical diagnostics requiring no extra hardware or software.
Advances in medical science are making more and more diseases treatable. And access to these treatments is increasing around the world. But to get the most from treatment researchers, doctors and patients also need access to accurate medical diagnostic tests. That’s our focus.
We began this work in 1984 when a team of leading virologists from Uppsala University in Sweden founded Cavidi. For over two decades we have been devoted to developing innovative solutions for the health and life science sector to give doctors in every part of the world the tools they need.
Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.
Cavidi is ISO9001 certified for quality management systems.
